Another Link Between Prostate Cancer Hormone Tx and Impaired Cognition
Hormonal therapy for advanced prostate cancer, particularly enzalutamide (Xtandi), had a significant association with cognitive impairment, an analysis of a large drug-safety database showed. Traditional hormonal therapy increased the odds of cognitive impairment by 47% versus men who did not receive the therapy. The odds more than doubled among men who received novel androgen receptor […]
Add-On Mavacamten Cuts Need for Septal Reduction in Obstructive HCM
WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported. In the VALOR-HCM study among 56 patients with documented oHCM who received add-on mavacamten to maximally-tolerated medical therapy, 17.9% met the composite endpoint (decision to move to SRT by week 16 or […]
A new brain-computer interface with a flexible backing: The flexible backing allows arrays of micro-scale needles to conform to the contours of the brain, which improves high-resolution brain recording
Engineering researchers have invented an advanced brain-computer interface with a flexible and moldable backing and penetrating microneedles. Adding a flexible backing to this kind of brain-computer interface allows the device to more evenly conform to the brain’s complex curved surface and to more uniformly distribute the microneedles that pierce the cortex. The microneedles, which are […]
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo
Advanced renal cell carcinoma (RCC) patients with high serum levels of troponin T had a greater risk of serious cardiac events when treated with an immune checkpoint inhibitor and VEGFR inhibitor combination, data from the phase III JAVELIN Renal 101 trial indicated. For patients assigned to the avelumab (Bavencio) plus axitinib (Inlyta) arm, 17.1% of […]
Immunotherapy Combo in Advanced RCC Led to More Time Off Treatment
Nearly one-fifth of patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC) treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the CheckMate 214 trial were alive and treatment free beyond 3 years. Among the phase III trial participants, the treatment-free survival (TFS) rate at 42 months was 18% for those who were randomized to […]
Bifunctional Protein Shows Promise in HPV-Related Cancers
A bifunctional fusion protein with immunotherapeutic activity proved active in advanced, difficult-to-treat cancers associated with human papillomavirus (HPV), according to pooled data from two prospective studies. Overall, 21 of 75 patients had confirmed responses with bintrafusp alfa, which inhibits tumor growth factor-beta (TGF-β) and PD-L1 interaction with its receptor. Responses were durable in many cases […]